HUMA Humacyte, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Humacyte, Inc. (HUMA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 27, 2026, a 10-Q quarterly report filed on November 12, 2025, an 8-K current report filed on April 24, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Humacyte, Inc. (HUMA) (SEC CIK 1818382), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Preliminary financial results for year ended December 31, 2025 disclosed under "Operational Updates"
- • No specific financial figures included in Item 2.02; refer to exhibit or press release for details
Item 8.01: Other Events
- • Suspension of $60M ATM equity offering prospectus limits near-term capital raise options using sales agreement with TD Cowen
- • Preliminary 2025 financials: $50.9M cash, $2.0M revenue incl. $1.4M product sales, 61 Symvess units sold, pending final audit
Item 7.01: Regulation FD Disclosure
- • Disclosure clarifies 7.01 filing not “filed” under Exchange Act Section 18 liability provisions
- • Information not incorporated by reference in future Securities Act or Exchange Act filings
Item 1.01: Entry into a Material Definitive Agreement
- • Registered direct offering of 25 million shares of common stock at $0.80 per share, raising gross proceeds of $20 million
- • Net proceeds expected around $18.4 million after placement agent fees and expenses
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Humacyte, Inc. (HUMA) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 24, 2026 | — | — | — |
10-K | Mar 27, 2026 | Dec 31, 2025 | — | |
8-K | Mar 19, 2026 | — | Analysis | — |
8-K | Mar 19, 2026 | — | Analysis | — |
8-K | Dec 16, 2025 | — | — | |
8-K | Dec 15, 2025 | — | — | |
8-K | Dec 15, 2025 | — | — | |
8-K | Nov 26, 2025 | — | — | |
10-Q | Nov 12, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 13, 2025 | Mar 31, 2025 | — | |
10-K | Mar 31, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 13, 2024 | Jun 30, 2024 | — | |
10-Q | May 13, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 14, 2023 | Jun 30, 2023 | — | |
10-Q | May 12, 2023 | Mar 31, 2023 | — | |
10-K | Mar 24, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 10, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 12, 2022 | Jun 30, 2022 | — | |
10-Q | May 13, 2022 | Mar 31, 2022 | — | |
10-K | Mar 29, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 15, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest HUMA SEC filings in 2026?
Humacyte, Inc. (HUMA) has filed a 10-K annual report on March 27, 2026, a 10-Q quarterly report on November 12, 2025, an 8-K current report on April 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did HUMA file its most recent 10-K annual report?
Humacyte, Inc. (HUMA) filed its most recent 10-K annual report on March 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view HUMA 10-Q quarterly reports?
Humacyte, Inc. (HUMA)'s most recent 10-Q quarterly report was filed on November 12, 2025. SignalX displays every HUMA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has HUMA filed recently?
Humacyte, Inc. (HUMA)'s most recent 8-K was filed on April 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find HUMA insider trading activity (Form 4)?
SignalX aggregates every HUMA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does HUMA file with the SEC?
Humacyte, Inc. (HUMA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HUMA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Humacyte, Inc. (HUMA).
What is HUMA's SEC CIK number?
Humacyte, Inc. (HUMA)'s SEC CIK (Central Index Key) number is 1818382. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1818382 to look up all HUMA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find HUMA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Humacyte, Inc. (HUMA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Humacyte, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 29+ filings.